Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its ...

Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd has announced that the European Commission (EC) has ...

Viking Therapeutics (VKTX 1.70%) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...

The global erythropoietin drugs market was valued at approximately USD 6.87 billion in 2022 and is projected to grow at a healthy growth rate of around 1.5% during the forecast period from 2023 to ...

US stocks on the S&P 500, Nasdaq and Dow rose as job data exceeded market expectations amid Trump tariff concerns. Job data ...

Remote monitoring and patient-initiated care match usual care in maintaining low disease activity in patients with axial ...

The global cancer monoclonal antibodies (mAbs) market , valued at $55.6 billion in 2021, is projected to reach $106.8 billion by 2031, growing at a CAGR of 7% from 2022 to 2031. This exponential ...

US stocks rose strongly on Thursday with the S&P 500 and Nasdaq both notching new record highs ahead of the long weekend after key labour market data came in well ahead of forecasts.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Alta Advisers boosted its Amgen stake by nearly 50% this quarter, owning shares worth $844,000 at last count. Vanguard, ...